ticlopidine has been researched along with Heart Septal Defects, Ventricular in 3 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Heart Septal Defects, Ventricular: Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower chambers of the heart. Classification of ventricular septal defects is based on location of the communication, such as perimembranous, inlet, outlet (infundibular), central muscular, marginal muscular, or apical muscular defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A perimembranous ventricular septal defect (7 mm) and an ostium secundum atrial septal defect (8." | 1.37 | [Simultaneous transcatheter treatment of perimembranous ventricular septal defect and secundum atrial septal defect in an adult: first application in Turkey]. ( Arı, H; Arı, S; Bozat, T; Koca, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arı, H | 1 |
| Arı, S | 1 |
| Koca, V | 1 |
| Bozat, T | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| Saitoh, H | 1 |
| Takayama, T | 1 |
| Matsumoto, H | 1 |
| Furuse, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
1 review available for ticlopidine and Heart Septal Defects, Ventricular
| Article | Year |
|---|---|
[Pregnancy and delivery of a patient with a prosthetic aortic valve treated with antiplatelet drugs: a case report].
Topics: Adult; Aortic Valve; Blood Platelets; Dipyridamole; Female; Heart Septal Defects, Ventricular; Heart | 1987 |
2 other studies available for ticlopidine and Heart Septal Defects, Ventricular
| Article | Year |
|---|---|
[Simultaneous transcatheter treatment of perimembranous ventricular septal defect and secundum atrial septal defect in an adult: first application in Turkey].
Topics: Anesthetics, Intravenous; Clopidogrel; Echocardiography, Transesophageal; Female; Fluoroscopy; Heart | 2011 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |